Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies
Intellia Therapeutics NTLA announced that it has expanded its existing collaboration with Regeneron Pharmaceuticals, Inc. REGN to develop additional in vivo CRISPR-based gene-editing therapies focused on neurological and muscular diseases.
Under the expanded collaboration, Regeneron will supply its proprietary antibody-targeted adeno-associated virus vectors and delivery systems, while Intellia will bring its proprietary Nme2 CRISPR/Cas9 systems, which have been adapted for viral vector delivery. This combination allows for precise modification of target genes, which are crucial in treating complex diseases.
Per the terms of the deal, the companies will initially focus on researching two in vivo non-liver targets. While Intellia will lead the design of the editing methodology, Regeneron will do the same for the targeted viral vector delivery approach.
Furthermore, each company will have the opportunity to lead the potential development and commercialization of product candidates for one target. The company which is not leading in development and commercialization will have the option to enter into a co-development and co-commercialization agreement for the target.
Intelia’s shares have lost 14.9% year to date compared with the industry’s 17.6% decline.
Image Source: Zacks Investment Research
Genomic editing, using the CRISPR technology to repair a defective genetic material that causes diseases, is probably one of the most promising and exciting healthcare innovations seen in decades. This technology has the potential to selectively delete, modify or correct a disease-causing abnormality in a specific DNA segment.
Intellia’s collaboration with Regeneron has given a boost to the former to develop its pipeline. In 2016, both the companies initially entered into a partnership to co-develop and commercialize CRISPR/Cas-based therapies primarily focused on genome editing in the liver. The collaboration was further expanded in 2020 to co-develop therapies for hemophilia A and hemophilia B.
NTLA is currently evaluating its in-vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis.NTLA-2001 is part of the company’s co-development and co-promotion agreement with REGN. While NTLA is the lead party in the deal, REGN shares 25% of the development costs and commercial profits.
Intellia Therapeutics, Inc. Price and Consensus
Intellia Therapeutics, Inc. price-consensus-chart | Intellia Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Intellia currently carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the same industry are Anika Therapeutics ANIK and Annovis Bio ANVS. While Anika Therapeutics currently sports a Zacks Rank #1 (Strong Buy), Annovis Bio carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 90 days, the Zacks Consensus Estimate forAnika Therapeutics has narrowed from a loss of $1.41 per share to a loss of $1.24 for 2023. The bottom-line estimate has widened from a loss of 79 cents to a loss of 82 cents for 2024 during the same time frame. Shares of the company have lost 36.3% year to date.
ANIK’s earnings beat estimates in one of the trailing four quarters and missed the mark in the remaining three, delivering an average negative surprise of 32.12%.
In the past 90 days, the Zacks Consensus Estimate for Annovis Bio has narrowed from a loss of $4.89 per share to a loss of $4.38 for 2023. The bottom-line estimate has narrowed from a loss of $3.18 to a loss of $2.77 for 2024 during the same time frame. Shares of the company have lost 33.8% year to date.
ANVS’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 13.40%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
Anika Therapeutics Inc. (ANIK) : Free Stock Analysis Report
Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report
Annovis Bio, Inc. (ANVS) : Free Stock Analysis Report
